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Background: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about
the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally
studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by
histopathological comparison.
Methods: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide
(LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg
bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment.
Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS
and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion,
hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall
thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used
as criteria for evaluating inflammation and efficacy of treatment.
Results: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant
improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening
and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant
improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction.
Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters.
Conclusions: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be
recommended as a first treatment choice based on its significant reducing lung injury and reparative effects.
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Sepsis is a systemic inflammatory response to infection
and a major cause of morbidity and mortality worldwide
[1]. Sepsis is characterized by progressive development
of conditions including systemic inflammatory response
syndrome (SIRS), tissue damage and multiple organ
dysfunction syndrome (MODS), and acute respiratory* Correspondence: dromeraraz@gmail.com
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stated.distress syndrome or acute lung injury (ARDS/ALI).
Although the pathophysiology of sepsis is not well
defined, monocytes orchestrate the innate immune
response to Gram-positive and Gram-negative bacteria
by expressing a variety of inflammatory cytokines, including
tumor necrosis factor (TNF)-a and interleukin (IL)-6, which
are believed to play an essential role in the pathogenesis
of sepsis [2-7].
ARDS/ALI, one of the potential complications of sepsis,
is a serious condition with a high mortality rate (30-50%).
Acute pulmonary inflammation is mediated by a number
of cytokines and reactive oxygen species (ROS) produced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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by ROS is caused by the oxidation of cell membrane lipid
moieties. ROS can be produced by activated macrophages,
endothelial cells, or polymorphonuclear neutrophils (PMN).
The infiltration of PMN is mediated by a chemokine
gradient and may be the key event that drives a pulmonary
oxidant damage [8].
To date, treatment strategies for ARDS/ALI have shown
limited success in improving clinical outcomes, with the
exception of low tidal volume mechanical ventilation [9].
Considering the evidence that inflammation contributes
to the pathogenesis of ARDS/ALI [10], therapies that
attenuate this inflammation – such as corticosteroids,
potent anti-inflammatory agents and immunomodulators,
which act in multiple stages of the inflammatory cascade
[11] – should be investigated. There are two opposing
views concerning the use of steroids in treating ARDS/
ALI. One criticism is that steroids are ineffective in the
early or late management of ARDS/ALI [12]; however,
there have been positive reports that the use of steroids
significantly increased survival [13]. Thus the role of
steroids in the treatment of ARDS/ALI is debatable.
Treatment options of ARDS/ALI also include experimen-
tal drugs reducing lung injury similar to corticosteroids.
Endothelin-1 (ET-1) receptor antagonist bosentan is one
of such drugs. Endothelin has four receptors (ET-A,
ET-B1, ET-B2 and ET-C) and bosentan exerts its effect
through ET-A and -B receptors [14,15]. ET-1 is a peptide
produced by endothelial cells and several studies have
demonstrated its important role in lung inflammation.
ET-1 has significant pro-inflammatory effects in airways
[16,17], whereas endothelin receptor antagonists mitigate
its pro-inflammatory effects in animal models of airway
inflammation [15,18]. Research into the reducing lung
injury of endothelin-1 receptor antagonists is ongoing.
In the current study, histopathologic techniques were
used to compare the efficacy of dexamethasone and two




A total of 25 male Wistar rats weighing 220–250 g were
used. All rats were obtained from Ataturk University’s
Experimental Animal Laboratory of the Medicinal and
Experimental Application and Research Center (ATADEM).
Animal experiments and procedures were performed in
accordance with national guidelines for the use and
care of laboratory animals and were approved by Ataturk
University’s local animal care committee (442190979-
01-02/2831). The rats were housed in standard plastic
cages on sawdust bedding in a climate-controlled room
(22 ± 1°C). Standard rat food and tap water were provided
ad libitum.Drugs and endotoxin
LPS from Escherichia coli serotype 0111:B4 (Sigma-
Aldrich Srl, Milan, Italy) was prepared in sterile saline,
aliquoted, and stored at -80°C for short periods. All
chemicals were purchased from Sigma Chemical Co.
(Munich, Germany). Bosentan was obtained from Actelion
Pharmaceuticals Ltd (Allschwil, Switzerland).
Experimental design
Experimental groups
Five experimental groups (5 rats per group) were used:
vehicle (saline) control (Group I); lipopolysaccharide (LPS) +
saline (Group II); LPS + dexamethasone (Group III); LPS +
50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg
bosentan (Group V).
Drug administration
Bosentan was administered orally one hour before and
12 hours after LPS treatment. Dexamethasone was
administered intraperitoneally in three doses of 1 mg/kg;
one dose was co-administered with LPS and the other
two doses were given 30 minutes before and after LPS
treatment. The groups were housed in separate cages.
Sepsis model
The animals in the vehicle control group (Group I)
received 1 ml salineintraperitoneally twice at an interval
of 30 minutes. One dose of 1 mg/kg LPS was administere-
dintraperitoneally to the animals in Groups II, III, IV
and V. All animals were monitored for 24 hours; none of
them perished during the observation period. All animals
were sacrificed after 24 hours by 50 mg/kg thiopental
sodium injection. The lungs were removed immediately
and washed with ice-cold saline. Tissues were fixed in
10% formalin for histopathological analysis.
Histological procedure
Histochemical methods
Rat pulmonary tissue samples were fixed in 10% formalin
for 2–4 days and embedded in paraffin. Sections of 4
micron thickness were taken and stained with hematoxylin-
eosin. Sections were evaluated by two independent patholo-
gists with an Olympus BX51 microscope according to the
following parameters: vasodilation-congestion, hemorrhage,
polymorphonuclear leukocyte (PMN) infiltration, mono-
nuclear leukocyte (MNL) infiltration, alveolar wall thicken-
ing, alveolar destruction/emphysematous appearance and
areas of focal organization. Parameters were assessed using
a 4-point grading system: Grade 0 = none; Grade 1 (+) =
mild; Grade 2 (++) = moderate; Grade 3 (+++) = severe.
Immunohistochemical methods
Immunohistochemistry was performed using a Leica
Bond-max automated immunostainer (Leica Microsystems,
Figure 1 H&E stained sections from saline control (Group I) (×100).
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col. The prepared 4-μm tissue sections were deparaffinized
in a dry oven, dewaxed in xylene and rehydrated through
graded alcohol. Heat pretreatment was performed in citrate
buffer (pH 6.0) at 100°C for 20 minutes. Sections were
treated with peroxide for 5 minutes, then anti-Endothelin
1 antibody (ab49591, rabbit monoclonal, 1:50; Abcam,
Cambridge, UK) was applied for 30 minutes. Antibody
binding was detected using a bond polymer refine kitFigure 2 H&E stained sections from LPS-only group. (A) arrowhead, he
thickening of the interalveolar septum, alveolar filling defects (H&E, ×100), (
(D) arrowhead, vasodilation-congestion, arrow, terminal bronchiole (H&E, ×(Leica Microsystems) and diaminobenzidinetetrahydrochlor-
ide solution (Kit HK153-5 K; Biogenex, San Ramon, CA,
USA) was used as a chromogen.
The analysis was done using an Olympus BX51 micro-
scope and the two analyzing pathologists were blind
regarding the group from which the sections belonged.
The staining proportion score was determined by percent
of cells stained: <10% stained = 1 (low); 10-50% stained = 2
(medium); ≥50% = 3 (high). The numerical value formorrhage, arrow, terminal bronchiole (H&E, ×100); (B) arrowhead,
C) arrowhead, PNL infiltration, arrow, MNL infiltration (H&E, ×200),
100).
Figure 3 H&E stained sections from Group III (dexamethasone) and IV (50 mg/kg bosentan). (A, B: Group III) tb, terminal bronchiole, cong,
congestion (H&E, ×100), (C, D: Group IV) ias,interalveolar septum (H&E, ×100).
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2, 3 (for light, medium and dark staining).Statistical analyses
The data were analyzed using SPSS version 17 statistical soft-
ware (SPSS Inc., Chicago, IL). One-way ANOVA followed by
Tukey’s test was used to analyze the inflammation within
groups. P < 0.05 was considered statistically significant.Figure 4 H&E stained sections from Group V (100 mg/kg
bosentan). (A) ias, interalveolar septum, Tb, terminal bronchiole
(×100), (B) (×200).Results
Histopathological results
Group I had the lowest scores in all parameters evaluated
in histochemical analyses (Figure 1). From all experimental
groups, Group II (LPS-only) had the highest scores and
most severe presentation in the parameters of vasodila-
tion-congestion, hemorrhage, PMN and MNL infiltra-
tion, alveolar wall thickening and emphysematous areas
(Figure 2). When compared to Group II, treatment with
dexamethasone (Group III), 50 mg/kg bosentan (Group
IV) (Figure 3) and 100 mg/kg bosentan (Group V) each
produced significant improvements in most parameters.
The amelioration of vasodilation-congestion was most
significant with 100 mg/kg bosentan (Group V). The
attenuation of inflammatory reaction (PMN and MNL
infiltration) and resolution of hemorrhage were similar
between 100 mg/kg bosentan and dexamethasone. The
reversal of focal organization was most marked with
100 mg/kg bosentan (Figure 4). In general, 50 mg/kg
bosentan effected improvement compared to LPS-only
treatment, but this improvement was not as pronounced
as with dexamethasone or 100 mg/kg bosentan.Immunohistochemical results
In immunohistochemical analyses, 100 mg/kg bosentan
showed the highest staining proportion and intensity
scores, followed by 50 mg/kg bosentan and dexamethasone
(Figure 5). Anti-endothelin-1 reactivity in the LPS-only
group (Group II) was higher than in controls (Group I),
but it was markedly lower compared to the treatment
groups (Groups III-V) (Figure 6).
Clinical results
Treatment with dexamethasone (Group III) resulted
in significant improvements in vasodilation-congestion
(p = 0.0001), hemorrhage (p = 0.0001), PMN (p = 0.002)
Figure 5 Proportion and intensity of anti-endothelin staining in
sections from Group V (100 mg/kg bosentan). (A) anti-endothelin
(LM, ×100); (B) anti-endothelin (LM, ×200).
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(p = 0.001) and emphysematous areas (p = 0.0001)
compared to the LPS-only group. Treatment with 50 mg/kg
bosentan (Group IV) also significantly mitigated hemor-
rhage (p = 0.0001), PMN (p = 0.031) and MNL (p = 0.0001)
infiltration, alveolar wall thickening (p = 0.001) and alveolar
destruction (p = 0.01). The reducing lung injury and
ameliorative effects of 100 mg/kg bosentan were signifi-
cant in all parameters (p = 0.0001) (Figure 7A-G).
When comparing parameters of reducing lung injury
between treatment groups (Groups III-V), focal organizationFigure 6 Proportion and intensity of anti-endothelin staining in sectio
Group II (LPS-only); (C) Group III (dexamethasone); (D) Group IV (50 mg/kgwas the only statistically significant difference between
dexamethasone and 100 mg/kg bosentan treatments
(p = 0.035). Vasodilation-congestion was the only para-
meter significantly different between 50 and 100 mg/kg
bosentan treatment (p = 0.002).
A computed tomography (CT) scan was performed
on a representative sample of one animal from each of
the following groups: saline control (Figure 8A), LPS-only
(Figure 8B), dexamethasone (Figure 8C) and 100 mg/kg
bosentan (Figure 8D).
Discussion
In this study, dexamethasone was shown to reduce lung
injury in an animal model of ALI; compared to dexametha-
sone, whereas bosentan demonstrated equal or greater
efficacy. Although the reducing lung injury of bosentan
at 50 mg/kg and 100 mg/kg was similar, the latter dose
caused greater improvement in focal organization, which
indicates overall repair. Furthermore, compared to the
other treatment groups, 100 mg/kg bosentan generally
effected the most significant improve-ment in all parame-
ters and resulted in the highest staining proportion and
intensity scores of all experimental groups.
The array of pathophysiological changes induced by
LPS challenge resemble those often accompanying Gram-
negative bacteria sepsis [19-22]. A common and frequently
lethal complication of sepsis is ARDS/ALI, which is
associated with pulmonary microvascular injury and is
characterized by severe hypoxemia, diffuse lung infiltra-
tion, reduction in compliance, and increased pulmonary
resistance [19,22,23].ns from Groups I-IV (LM, ×100). (A) Group I (saline control); (B)
bosentan).
Figure 7 Comparison of vasodilation-congestion (A) hemorrhage (B) polymorphonuclear (PMN) leukocyte infiltration (C) mononuclear
leukocyte (MNL) infiltration (D) alveolar wall thickening (E) alveolar destruction-emphysematous appearance (F) and focal organization
between Group II (LPS-only) and Group V (100 mg/kg bosentan). *p = 0.0001 for A, B, D, E and F, p = 0.002 for C, and p = 0.001 for G.
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Figure 8 (A) Unenhanced Thoracic CT scan shows lung parenchyma (A) LPS-induced ARDS model showing diffuse alveolar opacities
(B) characteristic bilateral diffuse airspace consolidations with a marked anteroposterior gradient; bilateral peripheral areas of hyperlucency
representing trapped air are also apparent (C) bilateral reduction in alveolar opacities compared to the LPS-only group (D).
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of phagocytes are mediating factors in LPS-induced
ARDS/ALI. Phagocytes are known to play a key role
in lung injury by a cascade effect: phagocytes release
oxidants and proteases that damage the pulmonary
endothelial and epithelial cells, thus disrupting the
alveolar-capillary unit [24,25]. Glucocorticoids such as
dexamethasone are used in the treatment of inflammatory
lung injuries due to their ability to inhibit phagocyte
migration to the site of injury and to partially suppress
phagocyte reactivity [26]. Dexamethasone pretreatment
has also reduced pulmonary elastase activity and chlor-
amine levels, further supporting the anti-inflammatory
effectiveness of dexamethasone. [27] In this study, dexa-
methasone treatment produced marked reducing lung
injury in all observed parameters (vasodilation-congestion,
hemorrhage, PMN and MNL infiltration, alveolar wall
thickening, alveolar destruction-emphysematous appear-
ance). These findings support the use of dexamethasone
as a treatment for ARDS/ALI.
Though not applied clinically, the endothelin receptor
antagonist bosentan is used to treat ARDS/ALI experi-
mentally. Although endothelin is commonly associated
with pulmonary hypertension due to its vasoconstrictive
effect, it is also a vasoactive peptide that acts as pro-inflammatory agent, stimulating the release of cytokines
and production of reactive oxygen species by PMN [28].
A previous study demonstrated that bosentan treatment
significantly reduced the production of reactive oxygen
species by PMN during acute lung inflammation [29].
Another study demonstrated diminished levels of the pro-
inflammatory cytokines TNFα, interleukin-1, interleukin-6
and interleukin-8 in rat pulmonary tissue following bosen-
tan treatment of induced emphysema [30]. Both doses
of bosentan used in the current study demonstrated
pronounced reduction of lung injury. Amelioration
of vasodilation-congestion was more significant with
100 mg/kg bosentan rather than with 50 mg/kg. The
100 mg/kg dose of bosentan showed the strongest
overall reduction of lung injury among all the treatment
groups; this may be attributable to the strong attenuation
of vasodilation, which facilitates cell migration. Further-
more, 100 mg/kg bosentan caused significant reduction
of focal organization, which indicates amelioration of
inflammation. These findings support the efficacy of
100 mg/kg bosentan as reducing lung injury agent.
Despite the known effects of endothelin receptor an-
tagonists on inflammation in lungs, their impact on the
production of reactive oxygen species by PMN following
induction of acute lung inflammation is not known [31].
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anti-endothelin-1 antibody was performed; staining propor-
tion and intensity were measured to represent prevalence
and quantity of endothelin receptor. These values and
PMN and MNL infiltration data were analyzed to assess
the effect of endothelin receptor on PMN-MNL migration.
Treatment with 100 mg/kg bosentan resulted in higher
anti-endothelin-1 staining proportion and intensity com-
pared to dexamethasone, but its effect on PMN-MNL
migration was similar, suggesting that prevalence and
quantity of the endothelin receptor antigen does not
affect PMN-MNL migration. However, 100 mg/kg bosentan
had the most significant effect on both focal organization
and receptor prevalence and quantity, which suggests
that an elevated level of endothelin receptor contributes to
ameliorating inflammation.
Conclusions
In conclusion, reducing lung injury of bosentan is com-
parable to that of dexamethasone in the treatment of
ALI. Bosentan at 100 mg/kg may be preferable as a first
treatment option due to its significant reducing lung
injury and ameliorating effects. However, larger clinical
trials of bosentan are needed.
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